Colorectal Cancer Clinical Trial
Official title:
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Verified date | November 2022 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.
Status | Completed |
Enrollment | 285 |
Est. completion date | July 7, 2016 |
Est. primary completion date | May 30, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically-confirmed adenocarcinoma of the colon or rectum in patients with unresectable metastatic (M1) disease - Patients with at least 1 uni-dimensionally measurable lesion of at least 10 mm per modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines - Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method - Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 - Men or women 18 years of age or older - Adequate hematologic, renal, hepatic, metabolic, and coagulation function Exclusion Criteria: - History of prior or concurrent central nervous system (CNS) metastases - Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma - Clinically significant cardiac disease - Clinically significant peripheral sensory neuropathy - Active inflammatory bowel disease - Recent gastroduodenal ulcer to be active or uncontrolled - History of interstitial lung disease - Recent pulmonary embolism, deep vein thrombosis, or other significant venous event - Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy - Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery. |
Country | Name | City | State |
---|---|---|---|
Belgium | Research Site | Charleroi | |
Belgium | Research Site | Edegem | |
Belgium | Research Site | Libramont | |
Belgium | Research Site | Sint-Niklaas | |
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | Edmonton | Alberta |
Canada | Research Site | Greenfield Park | Quebec |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Oshawa | Ontario |
Canada | Research Site | Quebec | |
Canada | Research Site | Vancouver | British Columbia |
Canada | Research Site | Victoria | British Columbia |
Germany | Research Site | Berlin | |
Germany | Research Site | Bielefeld | |
Germany | Research Site | München | |
Germany | Research Site | München | |
Germany | Research Site | Magdeburg | |
Germany | Research Site | Passau | |
Germany | Research Site | Regensburg | |
Germany | Research Site | Würzburg | |
Italy | Research Site | Alba (CN) | |
Italy | Research Site | Fano | |
Italy | Research Site | Genova | |
Italy | Research Site | Mantova | |
Italy | Research Site | Udine | |
Italy | Research Site | Varese | |
Spain | Research Site | A Coruña | Galicia |
Spain | Research Site | Elche | Comunidad |
Spain | Research Site | Málaga | AndalucÃ-a |
Spain | Research Site | Sabadell | Cataluña |
Spain | Research Site | San Sebastián De Los Reyes | Madrid |
Spain | Research Site | Santander | Cantabria |
United States | Research Site | Akron | Ohio |
United States | Research Site | Albuquerque | New Mexico |
United States | Research Site | Alpharetta | Georgia |
United States | Research Site | Augusta | Georgia |
United States | Research Site | Austin | Texas |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Berkeley | California |
United States | Research Site | Bethesda | Maryland |
United States | Research Site | Beverly Hills | California |
United States | Research Site | Birmingham | Alabama |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Boynton Beach | Florida |
United States | Research Site | Buffalo | New York |
United States | Research Site | Burbank | California |
United States | Research Site | Chesapeake | Virginia |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Coral Springs | Florida |
United States | Research Site | Corpus Christi | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Danville | Kentucky |
United States | Research Site | Daytona Beach | Florida |
United States | Research Site | Denver | Colorado |
United States | Research Site | East Setauket | New York |
United States | Research Site | Fountain Valley | California |
United States | Research Site | Greenville | South Carolina |
United States | Research Site | Gurnee | Illinois |
United States | Research Site | Hazard | Kentucky |
United States | Research Site | Hershey | Pennsylvania |
United States | Research Site | Hollywood | Florida |
United States | Research Site | Huntersville | North Carolina |
United States | Research Site | Huntsville | Alabama |
United States | Research Site | Indianapolis | Indiana |
United States | Research Site | Kalamazoo | Michigan |
United States | Research Site | La Verne | California |
United States | Research Site | Lake Worth | Florida |
United States | Research Site | Lambertville | Michigan |
United States | Research Site | Lansing | Michigan |
United States | Research Site | Memphis | Tennessee |
United States | Research Site | Mount Pleasant | South Carolina |
United States | Research Site | Mountain Lakes | New Jersey |
United States | Research Site | Newport News | Virginia |
United States | Research Site | Newport News | Virginia |
United States | Research Site | Orange | California |
United States | Research Site | Overland Park | Kansas |
United States | Research Site | Paducah | Kentucky |
United States | Research Site | Peoria | Illinois |
United States | Research Site | Philadelphia | Pennsylvania |
United States | Research Site | Post Falls | Idaho |
United States | Research Site | Raleigh | North Carolina |
United States | Research Site | Riverside | California |
United States | Research Site | Roseville | California |
United States | Research Site | Round Rock | Texas |
United States | Research Site | Savannah | Georgia |
United States | Research Site | Sparta | New Jersey |
United States | Research Site | Spokane | Washington |
United States | Research Site | Stamford | Connecticut |
United States | Research Site | Staten Island | New York |
United States | Research Site | Temple | Texas |
United States | Research Site | Tyler | Texas |
United States | Research Site | Vancouver | Washington |
United States | Research Site | Waterbury | Connecticut |
United States | Research Site | White River Junction | Vermont |
United States | Research Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Belgium, Canada, Germany, Italy, Spain,
Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8. — View Citation
Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119. — View Citation
Heinemann V, Rivera F, O'Neil BH, Stintzing S, Koukakis R, Terwey JH, Douillard JY. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2016 Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1. — View Citation
Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24. — View Citation
Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open. 2018 Feb 24;3(2):e000297. doi: 10.1136/esmoopen-2017-000297. eCollection 2018. — View Citation
Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17. — View Citation
Rivera F, Karthaus M, Hecht JR, Sevilla I, Forget F, Fasola G, Canon JL, Guan X, Demonty G, Schwartzberg LS. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017 Aug;32(8):1179-1190. doi: 10.1007/s00384-017-2800-1. Epub 2017 Apr 19. — View Citation
Sartore-Bianchi A, Garcia-Alfonso P, Geissler M, Kohne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2021 Dec;20(4):305-313. doi: 10.1016/j.clcc.2021.05.007. Epub 2021 May 25. — View Citation
Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31. — View Citation
Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29. — View Citation
Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol. 2018 Feb;144(2):321-335. doi: 10.1007/s00432-017-2534-z. Epub 2017 Oct 28. Erratum In: J Cancer Res Clin Oncol. 2018 Feb 15;: — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (PFS) | PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Overall Survival | Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Percentage of Participants With an Objective Response | Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Duration of Response | For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Time to Disease Progression | Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Time to Initial Objective Response | For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Resection Rate | The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS) | PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Overall Survival in Participants With Wild-type RAS | Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Overall Survival in Participants With Wild-type RAS / BRAF | Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Percentage of Participants With an Objective Response for Participants With Wild-type RAS | Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.
Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. |
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF | Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. | From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks. | |
Secondary | Number of Participants With Adverse Events (AEs) | Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. | The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |